New Study Finds Aspartame, Common Artificial Sweetener, May Raise Risk of Heart Attacks
Aspartame is one of the most widely consumed food additives in the world. Found in diet sodas, sugar-free gum, tabletop sweeteners, flavored yogurts, protein powders, and thousands of other products marketed to health-conscious consumers, it has long been positioned as a safe calorie-free alternative to sugar. But a growing body of research — including a high-profile study published in the journal Cell Metabolism — has raised serious questions about aspartame's cardiovascular safety, specifically its potential role in raising the risk of heart attacks.
This article reviews what the research actually found, how aspartame may affect cardiovascular risk, what the regulatory bodies currently say, and what individuals who regularly consume aspartame should know.
The Study That Sparked the Concern
The research attracting the most attention was conducted by a team at the Cleveland Clinic and published in Nature Medicine in 2023. The investigators began with a large-scale metabolomics study — measuring thousands of metabolites in the blood of more than 1,100 patients undergoing cardiac evaluation — and discovered that a compound called phenylalanine was strongly associated with higher rates of major adverse cardiac events (MACE), including heart attacks, strokes, and death from cardiovascular causes.
This alone was not surprising, as phenylalanine is an amino acid found naturally in many proteins. What was notable was that the association between phenylalanine and cardiovascular events was significantly more pronounced in patients who also had elevated markers of platelet reactivity — specifically, a pathway through which platelets aggregate and form clots. The investigators then moved to animal studies, demonstrating that dietary aspartame increased phenylalanine levels in the blood and enhanced platelet activation in a thrombosis-relevant way. When given aspirin (which inhibits platelet aggregation), the elevated clotting response was partially reversed, suggesting the mechanism was platelet-mediated rather than simply correlational.
A follow-up analysis in a second independent cohort of approximately 2,100 patients confirmed the association between elevated phenylalanine and cardiovascular events. The researchers estimated that the phenylalanine elevation observed in aspartame consumers was associated with a roughly 50-66% increased risk of MACE compared to those without the elevation — a finding striking enough to generate significant scientific and media attention.
Why Aspartame Raises Phenylalanine Levels
Aspartame is a dipeptide — a compound composed of two amino acids, aspartic acid and phenylalanine, joined by a methyl ester. When aspartame is consumed and metabolized, it releases free phenylalanine into the bloodstream. This is why products containing aspartame carry a warning label for people with phenylketonuria (PKU) — a genetic disorder that prevents the normal metabolism of phenylalanine — but the new research raises the question of whether lower-level phenylalanine elevations in the general population also carry meaningful risk.
The phenylalanine released from aspartame is chemically identical to the phenylalanine in dietary protein, but the metabolic context differs: aspartame delivers phenylalanine without the co-ingested amino acids, fats, and fiber that accompany protein sources, potentially producing a more acute spike in circulating phenylalanine levels. The Cleveland Clinic researchers propose that this spike — combined with preexisting cardiovascular risk factors — may activate platelet aggregation pathways in a clinically relevant way. Managing cardiovascular risk factors comprehensively — including blood sugar, blood pressure, and inflammatory markers — becomes particularly relevant for people who use aspartame as a tool to reduce caloric intake.
What the WHO Said About Aspartame in 2023
The World Health Organization's International Agency for Research on Cancer (IARC) classified aspartame as "possibly carcinogenic to humans" (Group 2B) in July 2023 — a classification it shares with approximately 300 other substances, including aloe vera extract and pickled vegetables. Importantly, the Group 2B classification does not mean a substance causes cancer; it means there is limited evidence in humans and less-than-sufficient evidence from animal studies, making definitive conclusions impossible with current data. The IARC classification is a hazard assessment, not a risk assessment — it says nothing about the dose at which harm, if any, might occur.
The WHO's Joint Expert Committee on Food Additives (JECFA) simultaneously reviewed aspartame and concluded that the evidence was not convincing enough to change the acceptable daily intake (ADI) of 40 mg per kilogram of body weight — a level that would require consuming roughly 9 to 14 cans of diet soda per day for a 70 kg person to exceed. Both the FDA and the European Food Safety Authority (EFSA) maintain that aspartame is safe at normal consumption levels, though both bodies noted that the cardiovascular research warrants continued investigation.
The Gut Microbiome Angle
Separate from the platelet aggregation mechanism, research published by the Weizmann Institute of Science in Nature found that non-nutritive sweeteners — including aspartame — alter the gut microbiome in ways that impair glucose metabolism in some individuals. In a randomized controlled trial, participants consuming saccharin or sucralose for two weeks showed measurable changes in gut microbiome composition and impaired glycemic responses. While aspartame's gut effects were less pronounced than saccharin and sucralose in this particular trial, the finding reinforced broader concerns about the assumption that non-caloric sweeteners are metabolically neutral. Gut health is increasingly understood as a major modifier of systemic health outcomes — including those related to cardiovascular risk — making the microbiome angle of sweetener research more than tangential.
The gut-heart connection operates through several pathways: the gut microbiome influences systemic inflammation, endothelial function, and the production of short-chain fatty acids that affect lipid metabolism. If artificial sweeteners alter the microbiome in ways that promote inflammatory or metabolically unfavorable bacterial communities, the cardiovascular implications could be significant even at doses well below the acceptable daily intake. The gut microbiome's sensitivity to dietary additives — including emulsifiers, artificial sweeteners, and refined carbohydrates — represents one of the more active frontiers in nutrition science.
Putting the Risk in Context
Epidemiological associations, even large and well-replicated ones, do not establish causation. The Cleveland Clinic study, while rigorous, relied on measurements in a population already undergoing cardiac evaluation — people who are disproportionately likely to have existing cardiovascular risk factors. Generalization to the broader healthy population requires caution. Additionally, the association between phenylalanine and cardiac events may reflect confounding: people who consume more aspartame may be doing so precisely because they already have metabolic or cardiovascular risk factors that motivate them to reduce sugar intake, making aspartame consumption a marker of preexisting risk rather than an independent cause of it.
This reverse causation problem is notoriously difficult to resolve in nutritional epidemiology and has plagued observational studies of artificial sweeteners for decades. Randomized controlled trials — where participants are randomly assigned to consume aspartame or a comparator and followed for hard outcomes like heart attacks — would be definitive, but running such trials over the decades required to observe cardiovascular events is practically challenging and ethically complex. The platelet aggregation mechanism proposed by the Cleveland Clinic team is biologically plausible and partially validated in animal models, but human mechanistic trials confirming the same pathway are still limited.
The Irony of Sweetener Use and Cardiovascular Health
Aspartame and other artificial sweeteners became widespread partly because of concerns about sugar's cardiovascular effects — elevated triglycerides, weight gain, insulin resistance, and systemic inflammation all result from chronic excess sugar consumption. The research now raises the uncomfortable possibility that the replacement for sugar carries its own cardiovascular risks through a different mechanism. If both sugar and its most common replacement affect cardiovascular risk — the former through metabolic dysregulation, the latter potentially through platelet activation — the implications for dietary guidance are significant. Reducing processed sugars from your diet remains a well-supported health strategy; the question is what to replace them with in ways that don't introduce a different set of risks.
The alternatives with the strongest safety profiles at present are water, plain sparkling water, unsweetened tea and coffee, and beverages sweetened with small amounts of actual sugar kept well within moderation. Among non-nutritive sweeteners, monk fruit extract and allulose have the least research suggesting harm, though neither has been studied at the scale of aspartame or sucralose and long-term data remain limited. The relationship between common compounds once assumed safe and long-term health outcomes continues to surprise researchers — a pattern that argues for moderation with any additive, however well-established its regulatory approval.
Who Should Be Most Cautious
The Cleveland Clinic researchers identified several subgroups for whom the phenylalanine-platelet connection may be most clinically relevant: people with existing cardiovascular disease or multiple cardiovascular risk factors (hypertension, diabetes, dyslipidemia, smoking), people who consume aspartame in large amounts daily across multiple product categories, and individuals with phenylketonuria or related disorders of phenylalanine metabolism. For these groups, reducing aspartame consumption while the mechanistic evidence continues to accumulate is a reasonable precautionary step, particularly since aspartame offers no nutritional value that cannot be obtained through other means.
For the general population without significant cardiovascular risk factors who consume aspartame occasionally, the absolute risk increase suggested by current research is likely small in magnitude even if the relative risk elevation is real. But "small in magnitude" operates differently at population scale — a 50% relative increase in a common event (myocardial infarction affects approximately 800,000 Americans annually) translates to a very large absolute number of events if the exposure is truly causal and affects a significant fraction of the population regularly consuming aspartame-sweetened products.
What to Actually Do With This Information
The evidence does not currently justify treating aspartame as a dangerous toxin or demanding its immediate regulatory restriction. It does justify approaching aspartame — and non-nutritive sweeteners generally — with greater caution than has been typical in dietary guidance over the past several decades. The long-held assumption that artificial sweeteners are entirely neutral alternatives to sugar is increasingly untenable in light of accumulating research on their gut, metabolic, and now potentially cardiovascular effects.
Practically, this means reading ingredient labels more actively to identify aspartame-containing products, reducing habitual daily consumption of diet sodas and artificially sweetened foods while the evidence develops, and prioritizing genuinely unsweetened alternatives where feasible. The foundations of healthy living — adequate sleep, physical activity, whole-food nutrition, and stress management — do more for cardiovascular health than any single dietary additive can harm or help. But within that framework, the emerging science on aspartame is a legitimate reason to reconsider the daily diet soda habit that millions of people assumed was a harmless indulgence in calorie reduction.
Comments
Post a Comment